PERSONALIS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.54 USD | -3.75% |
|
+21.74% | -26.67% |
Presentation Operator MessageOperator (Operator)Good day, and thank you standing by. Welcome t...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Companyâs advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Companyâs tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.
Calendar
2024-05-08
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.54
USD
Average target price
4.6
USD
Spread / Average Target
+198.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.67% | 78.86M | |
| +25.69% | 47.9B | |
| +46.90% | 41.42B | |
| -3.46% | 40.7B | |
| -6.20% | 28.92B | |
| +9.17% | 25.55B | |
| -20.42% | 19.27B | |
| +0.17% | 12.15B | |
| +28.07% | 12.14B | |
| -1.24% | 11.99B |
- Stock Market
- Equities
- PSNL Stock
- News Personalis, Inc.
- Transcript : Personalis, Inc., Q2 2022 Earnings Call, Aug 03, 2022
